Literature DB >> 15355753

Anticraving agents for the treatment of addictive disorders.

Charles P O'Brien.   

Abstract

Entities:  

Year:  2004        PMID： 15355753     DOI： 10.1007/s11920-004-0017-9

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


× No keyword cloud information.
  5 in total

1.  Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects.

Authors:  M E McCaul; G S Wand; T Eissenberg; C A Rohde; L J Cheskin
Journal:  Neuropsychopharmacology       Date:  2000-05       Impact factor: 7.853

2.  Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

Authors:  Stephanie S O'Malley; Suchitra Krishnan-Sarin; Conor Farren; Rajita Sinha; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2002-01-22       Impact factor: 4.530

3.  Effects of naltrexone on alcohol self-administration in heavy drinkers.

Authors:  D Davidson; T Palfai; C Bird; R Swift
Journal:  Alcohol Clin Exp Res       Date:  1999-02       Impact factor: 3.455

4.  Naltrexone in the treatment of alcohol dependence.

Authors:  J R Volpicelli; A I Alterman; M Hayashida; C P O'Brien
Journal:  Arch Gen Psychiatry       Date:  1992-11

5.  The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings.

Authors:  M J Bohn; T F Babor; H R Kranzler
Journal:  J Stud Alcohol       Date:  1995-07
  5 in total
  2 in total

1.  Role of acetylcholine transmission in nucleus accumbens and ventral tegmental area in heroin-seeking induced by conditioned cues.

Authors:  W Zhou; H Liu; F Zhang; S Tang; H Zhu; M Lai; P W Kalivas
Journal:  Neuroscience       Date:  2006-12-19       Impact factor: 3.590

2.  Pharmacological management of binge eating disorder: current and emerging treatment options.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Anne M O'Melia
Journal:  Ther Clin Risk Manag       Date:  2012-05-08       Impact factor: 2.423
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.